Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556469 | 0.69 | ESR1 (0.37) | ALDH1A1MAPTKMT2AKIF11 | |
| SCHEMBL3885846 | 0.69 | RAB9A (0.39) | GAAALDH1A1MAPT | |
| SCHEMBL30527736 | 0.68 | MCL1 (0.36) | NAPRTGAADAOALDH1A1LMNA | |
| SCHEMBL26130361 | 0.64 | HTT (0.45) | GAAKDM4EALDH1A1TSHRKMT2A | |
| SCHEMBL938488 | 0.64 | — | — | |
| SCHEMBL16291596 | 0.63 | KDM4C (0.37) | KDM4E | |
| SCHEMBL15352654 | 0.63 | TACR3 (0.43) | GAAFAAHKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL9052963 | 0.63 | TACR3 (0.43) | GAAFAAHKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL23144137 | 0.62 | — | — | |
| SCHEMBL21724773 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170879-B1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2013-01-16 | — | — | EP | disclosed |
| US-8008279-B2 | Compound—827 | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| EP-2170879-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| CN-101687864-A | 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors | ASTRAZENECA AB | 2010-03-31 | — | — | CN | disclosed |
| WO-2009001129-A9 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | WO | disclosed |
| US-20090012077-A1 | Novel Compound - 827 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| WO-2009001129-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012077-A1 | Novel Compound - 827 | CTSS, CTSF, CTSB | NAPRT 4021/4885GAA 51/4885FAAH 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.